|Systematic (IUPAC) name|
|(what is this?)|
Nelivaptan (INN), codenamed SSR-149,415, is a selective and orally active non-peptide vasopressin receptor antagonist selective for the V1b subtype. The drug had entered clinical trials for treatment of anxiety and depression. In July 2008, Sanofi-Aventis announced that further development of this drug had been halted.
- World Health Organization (2007). "International Nonproprietary Names for Pharmaceutical Substances (INN). Proposed INN: List 98". WHO Drug Information 21 (4): 341.
- Griebel G, Simiand J, Serradeil-Le Gal C, Wagnon J, Pascal M, Scatton B, Maffrand JP, Soubrie P (2002). "Anxiolytic- and antidepressant-like effects of the non-peptide vasopressin V1b receptor antagonist, SSR149415, suggest an innovative approach for the treatment of stress-related disorders". Proc. Natl. Acad. Sci. U.S.A. 99 (9): 6370–5. doi:10.1073/pnas.092012099. PMC 122955. PMID 11959912.
- Serradeil-Le Gal C, Wagnon J, Tonnerre B, Roux R, Garcia G, Griebel G, Aulombard A (2005). "An overview of SSR149415, a selective nonpeptide vasopressin V(1b) receptor antagonist for the treatment of stress-related disorders". CNS Drug Reviews 11 (1): 53–68. doi:10.1111/j.1527-3458.2005.tb00035.x. PMID 15867952.
- "Second-quarter 2008 results". Press Release. Sanofi-Aventis. 2008-07-31. Retrieved 2009-06-10.
It has been decided to discontinue the development of amibegron and SSR 149415 (a V1B receptor antagonist).
|This hormonal preparation article is a stub. You can help Wikipedia by expanding it.|